EP08.01-081 A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab

Category Primary study
JournalJournal of Thoracic Oncology
Year 2022
This article has no abstract
Epistemonikos ID: c0a0c19ef4b7efb96cf8ab2bfad10fb6e6f4446b
First added on: Feb 15, 2025